Pankaj Malhotra, MD
Pankaj Malhotra, MD is a Professor In-charge of Clinical Hematology at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The institute was created by the special act of the Indian Parliament. The attached Nehru hospital to this institute has more than 2200 beds. The Department of Clinical Hematology annually sees approx. 46000 new and follow-up adult patients with hematological disorders referred predominantly from northwest states of India. Dr. Pankaj Malhotra is heading the division that also runs a 3-years fellowship course (DM Clinical Hematology). Dr. Pankaj Malhotra did his MD in 1996. He was awarded the Indian Council of Medical Research Fellowship to Dept. of Hematology at Mayo Clinic Rochester in 2005. He has Fellowships from the Royal College of Physicians (London and Edinburgh).
Prof. Malhotra was a member of the organizing committee for the 2017 International Myeloma Workshop, in New Delhi. He is the founder President of the Indian Myeloma Academic Group (IMAGe). This group is involved in organizing annual myeloma conferences in India since 2016. Dr. Pankaj Malhotra is a member of ASTCT guidelines on hematopoietic cell transplantation and cellular therapy in multiple myeloma. He is a member of the Indian Council of Medical Research guidelines on multiple myeloma. He is also a member of National Cancer Grid guidelines on hematopoietic neoplasms including multiple myeloma. He is one of the authors of Asian Myeloma Network guidelines on the management of multiple myeloma in resource constraint settings. He has 461 publications in peer-reviewed journals to his credit, 20 book chapters, supervised 108 MD, DM, Ph.D. thesis. He is the principal investigator of many drug trials and 37 research projects that are ongoing or completed. He is a regular expert for patient related activities of NGO the “Myeloma Friends”.
He plans improving myeloma-related care, teaching and research in resource constraint settings especially in Asian countries with the help of myeloma colleagues already practicing in these areas.
